Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
EHVVF interview coming!
dog chit will always be dog chit
EHVVF
EHVVF Ludlow Research projects bullish outlook!
https://ludlowresearch.com/ehvvf-bullish-outlook-mental-health-crisis/
Stock at key breakout point
This could suddenly make run for .01+ here
NEWS OUT!
https://finance.yahoo.com/news/ehave-shareholder-ceo-ben-kaplan-130000012.html
MIAMI, Dec. 07, 2022 (GLOBE NEWSWIRE) -- Ehave, Inc., (OTC Pink: EHVVF) (the “Company”), a Healthcare Analytics provider with interests in the psychedelic and mental health sectors, today issued a letter to shareholders from its Chief Executive Officer, Ben Kaplan.
Dear Fellow Shareholders
As 2022 draws to a close, many of us will reflect on a year that saw global economic activity experiencing a broad-based and sharper-than-expected slowdown, increased inflation higher than we have seen in several decades, and higher interest rates. Despite these challenges and many others, I am very proud of our Ehave team's accomplishments in advancing our business plan. Our team executed several vital acquisitions, expanded our research capabilities, and realized many more achievements in our effort to continue to build on our strong foundation.
At the outset, I would like to provide an update on the triangular merger between our publicly traded Mycotopia Therapies (OTC: TPIA) subsidiary, Ei.Ventures, and PSLY.com. The $380 million transaction is structured to close when PSLY.com receives approval for trading on NASDAQ. We are following the procedures for this process as set forth by NASDAQ and the SEC. All parties involved are committed to completing the transaction. This transaction is important to Ehave shareholders because Ehave owns approximately 9,793,754 shares of Mycotopia Therapies. I expect to provide additional updates on this transaction and how it will affect our Ehave shareholders in the near future.
KetaDASH
I want to highlight several significant milestones our Ehave team has achieved in 2022. In February, Ehave purchased 100% of Rejuv IV, a mobile IV therapy provider in the San Francisco Bay Area. Rejuv IV became KetaDASH, a wholly owned subsidiary of Ehave, Inc. KetaDASH provides mobile Ketamine treatments for treatment-resistant depression, anxiety, PTSD, and other conditions, as well as IV infusions with fluids, essential vitamins, minerals, and electrolytes to enhance the health and wellness of its patients. After an initial telemedicine visit, a team of experienced physicians, therapists, and nurses administer every KetaDASH treatment in the patient's home, office, or mobile location. This innovative service departs from in-clinic intravenous, treatment, or unsupervised telehealth models to an at-home ketamine administration with telehealth and in-person medical supervision.
A typical KetaDASH experience incorporates a prescribing doctor, a nurse for administration and monitoring, and psychotherapists for integration, all from the comfort of the patient's home. Our KetaDASH team is pioneering efforts in precision medicine through Ehave’s partnership with Entheon Biomedical Corp.’s (CSE: ENBI) (OTCQB: ENTBF) HaluGen Life Sciences division. Our KetaDASH subsidiary is one of the first psychedelic companies to test patients with HaluGen’s expanded psychedelics genetic testing panel. This panel analyzes a series of relevant DNA biomarkers and utilizes pre-screening mental health surveys in order to provide insights into an individual's risk and potential for adverse reactions with the use of ketamine. Ehave's KetaDASH subsidiary is fully operational in Sacramento and San Francisco.
KetaDASH Miami
In June, Ehave took delivery of its first mobile KetaDASH unit, a custom high-end medical van utilizing KetaDASH's software platform. The KetaDASH Mobile Unit was specifically designed to focus on the efficacy of the treatment in a relaxed setting with the patient’s safety and comfort in mind. At the present time, KetaDASH is focusing on health, wellness, and mental health in the Miami area. KetaDASH currently does not offer ketamine treatments in Miami, but plans to start offering them in the first half of 2023.
KetaDASH Miami currently offers IV infusions with fluids, essential vitamins, minerals, and electrolytes to enhance the health and wellness of its patients. These infusions include IV Drip Detox and Hangover Cures, IV Vitamin Therapy for Pain Management, IV Hydration Therapy for Health & Wellness, and IV Therapy for Athletic Advantage and Fitness Recovery. Every infusion is administered by a qualified health care professional to ensure the safety of our patients.
Follow KetaDASH on Instagram at www.instagram.com/ketadash.usa.
MetaHealthU
MetaHealthU provides patients with a way to integrate providers, create troves of usable data for researchers, and clinicians to improve the care our nation's health system provides to its patients, providing a platform for precision health and giving patients ownership of their data. MetaHealthU focuses on interoperability, population health, and data ownership, and it has created a system that will work by providing patients the opportunity to own their health data.
We reached a milestone of 600 new users on our MetaHealthU platform during the last half of the year. The new users have found tremendous success with the platform and have compiled usable data on specific medical conditions like erectile dysfunction and fatigue. Many of these users have also used our mobile services in KetaDASH Miami.
Our Ehave team developed MetaHealthU as a powerful mobile application platform that empowers individuals to take complete control of their health and their healthcare data. With MetaHealthU, users can securely track all their health data from wearables, Electronic Health Records Systems (EHRs), doctors, and medical labs. The app is available for iOS 11.0 or later and Android. It includes a "digital file cabinet" for medical records. Users can log into their patient portals on various healthcare systems and medical labs and download their medical records in the digital file cabinet. Its features include easy-to-use navigation and search capabilities for users to collect, file, and tag their medical records on a mobile device. More information on MetaHealthU, as well as a free download of the app, can be found at https://apps.apple.com/us/app/metahealthu/id1600512401.
MetaHealthYuru
MetaHealthYuru is a personal mental health monitor that screens for early signs of mental health conditions, such as stress and depression. MetaHealthYuru uses voice analysis to screen for early signs of mental health conditions using a speech-based AI technology. Our MetaHealthYuru platform could potentially predict risk for various types of depression and mood and anxiety-based disorders years before a clinical diagnosis is obtained. This is accomplished by using vocal biomarkers to recognize your real emotional state and mood while tracking your mental health. Our technology can help detect and monitor subtle changes in the mental state by assessing individuals more frequently and objectively than the assessments used today. MetaHealthYuru can track your emotions and mood, analyze your mental state, and suggest potential treatments available for improving your mental well-being.
2023 and Beyond
In 2022 our Ehave team focused its efforts on developing our existing projects. We started the year with a large number and developed suitable metrics to gauge which ones will benefit the most from our resources. Moving forward, we intend to unlock the value created with our Mycotopia Therapies subsidiary and some of the company’s other investments. We also intend to focus our efforts on expanding our KetaDASH and MetaHealthU subsidiaries to propel Ehave into 2023 and beyond.
Ludlow who? Lololol
Dog chit
lol nobody's buying anything from this dog chit company
Anxiety & depression could surge in 2023
With markets, economy, and just all the craziness going on there no doubt we should see real crisis in anxiety and depression.
This only increases EHVVF business outlook.
You get some traders who suffer from anxiety to buy stock that would send EHVVF running for so many suffer from that and depression.
Health data could be worth millions
This type of data biotech firms would want to purchase for clincal trials.
Ehave at Web3 Summit (new tweets)
Company is starting to show life with focus on health data and web3
MetaHealthU = health data management
Building data sets up patient health that could be sold to biotech firms doing clinical trials for become big money for EHVVF
EHVVF Healthcare data management
Nice! I got some of this and keeping my eyes open. Love deals!
EHVVF 10% discount for Thanksgiving!!!
Sell NFT data for biotech firms
I just saw volume
New tweets and volume picking up.
Now like to see that spill over to $TPIA for that S-4 merger deal is moving closer to closing
Some great volume coming in today guys!!!
Ehave and NFTs smart moves!!!
$EHVVF - MetaHealthu
— Ehaveinc $EHVVF (@Ehaveinc1) November 15, 2022
Utilizing #NFTs for health data and clinical researchers
Putting power back in the patient's hands! pic.twitter.com/QHosRZcjCf
Tweet, signs of life (photos)
Ehave $EHVVF had great time attending, and bringing the CureDash van, to the #Microdose Wonderland conference in Miami early this month#psychedelics #anxiety #despression #PTSD pic.twitter.com/9mqCaJtpHN
— Ehaveinc $EHVVF (@Ehaveinc1) November 15, 2022
TPIA moving up
Looks like 10Q filed, and with updated S-4 this is moving closer to NASDAQ listing
https://www.otcmarkets.com/stock/tpia/overview
Prop122 Passes!!!
....many sites thought it passed yesterday but was so close counting went on till last night. NOW prop 122 has passed! Bullish for psychedelic sector.
Colorado passed prop 122 - Psychedelics legal
TPIA - S-4 updated
This moving one step closer to approval and NASDAQ listing
https://www.sec.gov/Archives/edgar/data/1931373/000109690622002636/psly_s4a.htm
TPIA .125 x .18
https://www.otcmarkets.com/stock/tpia/quote
Tweet says news coming!
Ai Venturtech will be interviewing the team at Ehave $EHVVF and how they use #AI and #MachineLearning to help treat people suffering from mental health issues such as #anxiety #depression and #PTSD
— AI Venturetech (@aiventuretech) November 4, 2022
Stay tuned for updates!https://t.co/zQVvMKFmzA
Positive Ketamine and games study - NPR
This agreement with TPIA is a huge step in the right direction. I'm holding!
https://finance.yahoo.com/news/ehave-announces-mycotopia-therapies-reaches-130000386.html
Interesting coverage here :
https://ludlowresearch.com/ehvvf-coverage-growing-mental-health-crisis-psychedelic/
lol, indeed!
EHVVF + TPIA =
Who needs help with the equation?
VA expanding ketamine for Veterans
VA community clinics expand Ketamine treatment options for depression
The largest ketamine therapy provider in the U.S. has expanded its relationship with the Department of Veterans Affairs’ Community Care Network to provide more ketamine treatments for veterans suffering from a variety of depressive disorders.
https://www.militarytimes.com/off-duty/military-culture/2022/09/29/va-community-clinics-expand-ketamine-treatment-options-for-depression/
TPIA a steal at .22
Worth gamble if NASDAQ merger goes off at 1.50 to 2.00
Wow really pumptastic!!!
Dog chit + dog chit = Dog chit(s)
Tpia + ehvvf = ?
Need help solving?
SEC update on TPIA merger
https://www.sec.gov/Archives/edgar/data/1931373/000109690622002459/psly_425.htm
ask 005, super cheap with ketamine demand growing
Worse economy gets more people will seek out treatments like ketamine and psychedelics to deal with the stress.
Dog chit + dog chit = more dog chit
Tpia + ehvvf = ?
Need help solving?
Followers
|
53
|
Posters
|
|
Posts (Today)
|
0
|
Posts (Total)
|
2523
|
Created
|
02/27/17
|
Type
|
Free
|
Moderators |
Volume | |
Day Range: | |
Bid Price | |
Ask Price | |
Last Trade Time: |